Compare PAYP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYP | EXEL |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.7B |
| IPO Year | 2026 | 2000 |
| Metric | PAYP | EXEL |
|---|---|---|
| Price | $20.43 | $41.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 21 |
| Target Price | $22.90 | ★ $46.45 |
| AVG Volume (30 Days) | ★ 4.6M | 2.7M |
| Earning Date | N/A | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | N/A | $13.66 |
| Revenue Next Year | N/A | $13.73 |
| P/E Ratio | ★ N/A | $14.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.80 | $32.38 |
| 52 Week High | $21.76 | $48.74 |
| Indicator | PAYP | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.32 |
| Support Level | N/A | $40.34 |
| Resistance Level | N/A | $46.46 |
| Average True Range (ATR) | 0.00 | 1.20 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 43.79 |
PayPay Corp is a Japan-based financial technology provider operating a digital finance platform that integrates payments, banking, credit, and investment services for individuals and businesses. Its platform connects users and merchants, facilitating a cashless ecosystem and providing an all-in-one solution for daily financial activities. The company operates in two reportable segments: i) Payment segment and ii) Financial service segment. The majority of the company's revenue is derived from the Financial service segment, which includes internet banking services, securities intermediary services and PayPay Point investment-related services, and loan management services. Geographically, it operates predominantly in Japan.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.